On the basis of the main role exerted by ERα in the development and progression of breast cancer and considering that this receptor is expressed in approximately 70% of breast tumors, the ER antagonist tamoxifen has been widely used, although its effectiveness is limited by de novo and acquired resistance [45]. This evidence concerns the gene ESR1 and breast neoplasm.